Nutra Pharma Names Top Biotech Executive, Dr. Harold Crews, as Chief Executive Officer.

Business Editors & Health/Medical Writers

BIOWIRE2K

Inventor of Coulter Corporation's Patents Covering Clinical Chemistry,

Immunochemistry and Blood Cell Analysis Comes to Nutra Pharma After

Coulter Sold to Beckman Instruments for Over $1 Billion

Nutra Pharma Corp. (OTCBB:NPHC) announced today that it has named Harold Crews as its Chief Executive Officer. Dr. Crews replaces Dr. Michael Flax, who will remain a director of Nutra Pharma Corp.

Dr. Crews, Chief Scientific Officer and Assistant to the Chairman of the Board of Coulter Corporation, was responsible for over 22 patents issued and pending and helped grow Coulter to over 5,000 employees with annual sales of $700 million. Dr. Crews attended the executive program at the Wharton School at the University of Pennsylvania.

Dr. Crews comes to Nutra Pharma after Coulter Corporation was sold to Beckman Instruments for over $1 billion. His expertise in molecular morphology and macromolecular cellular biochemistry will help Nutra Pharma monetize the intellectual property and drug candidates developed by Bio Therapeutics Inc., its pending acquisition.

Bio Therapeutics, founded in 1984 as Phylomed Inc., has developed a proprietary and patented method for altering the three-dimensional structure of certain proteins and peptides that results in the preservation of receptor-binding characteristics. The binding of specialized signaling proteins and peptides to cell surface receptors is an important part in the pathogenesis and progression of many different diseases. By modifying peptides which do not activate the normal biochemical pathways necessary for disease progression, powerful therapeutic agents could restore normal function to diseased tissue or exert a beneficial immunomodulatory effect.

"After an in-depth review of Bio Therapeutics' peptide-altering platform technology and promising drug candidates, I believe the Company is in a strong position to offer the biopharma world a host of beneficial products," said Dr. Crews, Chief Executive Officer.

The Company's research has yielded a breakthrough class of therapeutic peptides collectively referred to as "Immunokines." This peptide technology has created new opportunities for the relief and treatment of a variety of devastating neurological and viral disorders, most of which are currently without satisfactory therapies. Immunokine has been shown to be beneficial in the treatment of cancers, HIV infections and herpes, as well as viral diseases specific to animals. Immunokine also has the potential to treat hepatitis C infections in humans.

About Bio Therapeutics Inc.

Bio Therapeutics Inc. is a biopharma company focused on the optimization of protein compounds in order to achieve maximum therapeutic practicability (enhanced efficacy, minimized toxicity and ease of administration). The Company is engaged in the discovery and development of novel peptide therapeutics and drug delivery systems for the treatment of several different human and companion animal diseases. Bio Therapeutics' core technology revolves around the derivation of specialized receptor-binding peptides from natural proteins and peptides found in nature. Product candidates include multiple sclerosis, HIV, herpes, hepatitis C and cancer.

This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Nutra Pharma Corp., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully, and the ability to complete before-mentioned transactions. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.